RxDoctor Payments Data

Angelica Villahermosa, APRN

Family · Las Vegas, NVNPI 1912505199

Payments from drug & device makers

What this record shows

This record is dominated by other: $11,400 of the $12,192 with a category attached, or 93.5%. Angiodynamics, Inc. accounts for 93.5% of it on its own, with 9 other manufacturers making up the rest. Among family clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,192in general payments, 2019–2025

Across 35 payments — averaging $348.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$11K
  • Philips North America LLC$225
  • Boston Scientific$128
  • AstraZeneca$124
  • Lilly USA, LLC$115
  • Boehringer Ingelheim$111
  • plus $89 from 4 others

What the payments were for

  • Food & beverage$7926%
  • Other$11,40094%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,192 in reported general payments places this provider in the 95th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$18,811
Medicare patients
39
Services billed
176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide26$35,091
MounjaroTirzepatide21$23,915
JardianceEmpagliflozin20$13,272
Albuterol Sulfate HfaAlbuterol Sulfate25$545
Levothyroxine Sodium40$363
Atorvastatin Calcium33$221
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide15$220
Amlodipine Besylate22$149
Ibuprofen11$109
Metformin Hcl18$107
Lisinopril14$87
Losartan Potassium11$83
Quetiapine Fumarate14$79

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$115$23,91521 claims
Boehringer IngelheimJardiance$111$13,27220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,501 family providers in Nevada.

Other family in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →